Economy

Research in Israel indicates that two doses of Pfizer are “99.96% effective”

Research indicates that nearly all cases of Covid are prevented with two doses of the Pfizer vaccine.  Data collected in Israel - which is leading the world in launching the vaccine - found that only 0.04 percent of those vaccinated with both doses had developed coronavirus infection.  Pictured: A man receives a dose of the Pfizer / BioNTech vaccine in Tel Aviv, Israel on Tuesday

Two doses of Pfizer ‘two 99.96% effective’: Research in Israel suggests that separating weeks of double strikes prevents all cases of Covid-19

  • Israeli research has found that only 0.04% of those vaccinated with two doses of the Pfizer / BioNTech vaccine developed Coronavirus.
  • Of the 700,000 people who were vaccinated, only 300 subsequently contracted Covid-19, while only 16 needed hospital treatment, according to preliminary data.
  • Research indicates the vaccine also protects against the more contagious British variant

Research indicates that nearly all cases of Covid are prevented with two doses of the Pfizer vaccine.

Data collected in Israel – which is leading the world in launching the vaccine – found that only 0.04 percent of those vaccinated with both doses had contracted the coronavirus.

Of the 700,000 people who were vaccinated, only 300 subsequently contracted the virus, while only 16 required hospital treatment, according to preliminary data released by Israeli health officials.

The research indicates that the vaccine also protects against the more contagious British variant of Covid-19.

Professor Eyal Leshem, an Israeli infectious disease specialist, said the reports were “very good news”. He added, “The initial results are absolutely amazing.

After one dose, cases decreased dramatically and after two doses, there was only 0.4 percent.

Time will tell, we still need to collect data, but these are very encouraging preliminary reports.

More than 30 percent of the population of Israel received the vaccine, with numerous studies conducted on its effectiveness.

Professor Leshem added: “ On the one hand, we are seeing very high rates of community transmission with 1,000 cases every day – the highest rates we’ve seen since the start of the outbreak.

But when we look specifically at the hundreds of thousands of Israelis who have been vaccinated, they are not infected.

Pictured: Health workers from the Maccabi Vaccination Center administer doses of the Pfizer / BioNTech vaccine inside the car park of Givatayim Shopping Center in Tel Aviv, Israel on Tuesday

Pictured: Health workers from the Maccabi Vaccination Center administer doses of the Pfizer / BioNTech vaccine inside the car park of Givatayim Shopping Center in Tel Aviv, Israel on Tuesday

And even in those few cases that do get infected, they are mildly ill – only a few people need to go to hospital, and a few are severely ill and need to be hospitalized.

“It is what we call real life, environmental evidence of vaccine efficacy – the high efficacy of the vaccine.”

He added that the majority of those vaccinated were over the age of 60, which made the results more attractive.

Initial studies also found a significant decrease in cases among those who took a single dose of the vaccine.

Israel provides Pfizer with weekly updates of its vaccine campaign data under a cooperation agreement.

  • A leaked document revealed that Iran will buy the Oxford-AstraZeneca vaccine through the back door despite the ban on British “unreliable” vaccines. Iran banned vaccines from the United Kingdom and the United States on January 8, but in a dramatic turn, the nation is said to be purchasing 36 million doses of the Oxford vaccine via India.
READ  Mining stocks are higher in a struggling UK market - and it's another tailwind

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *